MEDP Q1 Earnings Call: Revenue Beats Expectations Amid Cancellations and Industry Headwinds

Clinical research company Medpace Holdings (NASDAQ:MEDP) announced better-than-expected revenue in Q1 CY2025, with sales up 9.3% year on year to $558.6 million. The company’s full-year revenue guidance of $2.19 billion at the midpoint came in 2% above analysts’ estimates. Its GAAP profit of $3.67 per share was 20.8% above analysts’ consensus estimates. The stock traded up 1% to $291.29 after reporting and hosting the earnings call.

Is now the time to buy MEDP? Find out in our full research report (it’s free).

StockStory’s Take

Medpace’s first quarter results were driven by a combination of higher-than-expected revenue and ongoing challenges in new business awards. Management attributed the revenue outperformance to faster progression of active clinical programs and a notable increase in reimbursable cost activity, rather than structural changes in execution. CEO August Troendle commented that "programs were progressing well," while CFO Kevin Brady identified "increases in reimbursable cost activity" as a key contributor.

Looking ahead, Medpace’s full-year guidance factors in both the elevated cancellation rates experienced in recent quarters and the expectation that backlog will continue to convert into revenue at a steady pace. Management was cautious about the environment, noting that sustained improvement in bookings will depend on a reduction in cancellations and a rebound in client funding conditions. Troendle emphasized that the ability to achieve higher book-to-bill ratios later in the year is "narrowed," but still possible if industry conditions improve.

Key Insights from Management’s Remarks

Medpace’s leadership discussed several factors shaping the first quarter, including customer funding pressure and shifting industry dynamics. The following points summarize management’s qualitative insights about the quarter’s performance:

• Bookings and Cancellations: Net new business awards and bookings declined due to elevated cancellations, especially in pre-backlog stages. Management noted funding difficulties among biotech clients as a primary driver.
• RFP Quality and Competition: While requests for proposals (RFPs) were strong, quality varied. Troendle explained that more CROs are being invited to bid, increasing competition and price pressure—often driven by clients seeking to secure funding for yet-unfunded projects.
• Customer Funding Challenges: The company observed that many cancellations were broad-based across customers but primarily linked to funding issues, with some project reprioritization and a few due to drug safety concerns.
• Revenue Outperformance Factors: CFO Kevin Brady said revenue was boosted by greater reimbursable cost activity and better-than-expected program progress, rather than any change in Medpace’s internal operational execution.
• Backlog Conversion and Visibility: Management expressed confidence in near-term revenue, as a sizable portion of backlog is expected to convert over the next twelve months, provided cancellation rates do not accelerate further.

Drivers of Future Performance

Management’s outlook for the remainder of the year hinges on stabilization in client funding and moderation in cancellation rates, with industry-wide funding constraints and competitive pressures influencing both revenue and margins.

• Funding Environment Uncertainty: The ability to achieve higher bookings and backlog growth later in the year depends on improved funding conditions for biotech clients and fewer cancellations. If cancellations persist, management expects book-to-bill ratios to remain around 1.0.
• Pricing Pressure and Competitive Dynamics: Increased competition for RFPs may result in price concessions and margin pressure, especially as more CROs are invited to bid on limited projects.
• Backlog Conversion and Program Progression: Near-term revenue visibility is supported by the current backlog, but any acceleration in project cancellations or funding withdrawals could impact revenue conversion and growth in future quarters.

Top Analyst Questions

• David Windley (Jefferies): Asked if increased CRO competition and price pressure were tied to weaker RFP quality; management confirmed more CROs are invited to bid, often for unfunded projects, and price sensitivity has increased.
• Max Smock (William Blair): Queried the potential downside to revenue if cancellations persist; Troendle stated most second-half revenue is “locked in,” but later-stage cancellations could still pose a risk.
• Ann Hynes (Mizuho): Sought specifics on cancellation rates and their drivers; management declined to provide exact rates but indicated cancellations are broad-based, mainly due to funding issues.
• Eric Coldwell (Baird): Inquired about the sustainability of backlog burn and whether improved execution played a role; CFO Brady said higher revenue and reimbursable activity, not execution changes, drove the increase.
• Jalindra Singh (Truist): Asked if Medpace’s focus on personalized service is being challenged by peers; Troendle stated there have been no material changes in competitive dynamics or Medpace’s approach.

Catalysts in Upcoming Quarters

In the quarters ahead, our analysts will focus on (1) the trajectory of cancellations and whether funding conditions for biotech clients stabilize, (2) Medpace’s ability to improve net bookings and backlog growth as the year progresses, and (3) any shifts in competitive dynamics or pricing pressure as more CROs vie for business. The sustainability of backlog conversion rates and the impact of ongoing client reprioritization will also be important indicators of future performance.

Is MEDP at an inflection point that warrants a buy or sell? The answer lies in our free research report.

The Best Stocks for High-Quality Investors

Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.

While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years.

Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Comfort Systems (+751% five-year return). Find your next big winner with StockStory today.